Scholarlink

<p>The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of the ONCOBIOME network in cancer microbiome research

  • 期刊论文

  • 发表日期：

    2025年4月11日

查看全文
  • Laurence Zitvogel,
  • Lisa Derosa,
  • Bertrand Routy,
  • Sibylle Loibl,
  • Lucie Heinzerling,
  • I. Jolanda M. de Vries,
  • Lars Engstrand,
  • Carolina Alves Costa Silva,
  • Daniela Barbieri,
  • Annemarie Boleij,
  • Kalijn Bol,
  • Nele Brusselaers,
  • Eva Budinska,
  • Carlos Caldas,
  • Francesca Cordero,
  • Chiara Cremolini,
  • Romain Daillère,
  • Carsten Denkert,
  • Sylvere Durand,
  • Stanislav Ehrlich,
  • François Eisinger,
  • Arielle Elkrief,
  • Katja Fall,
  • Baerbel Felder,
  • Gladys Ferrere,
  • Marine Fidelle,
  • Jérôme Gaborit,
  • Manuela Gariboldi,
  • Cheick Oumar Guindo,
  • Valerio Iebba,
  • Janne Lehtio,
  • Magalie Martineau,
  • Meriem Messaoudene,
  • Florence Monville,
  • Alessio Naccarati,
  • Barbara Pardini,
  • Federica Pinto,
  • Gianmarco Piccinno,
  • Eugénie Pizzato,
  • Vlad Popovici,
  • Maan Haj Rachid,
  • Sonia Tarallo,
  • Beatrice Schuler-Thurner,
  • Gerold Schuler,
  • Zoltan Szallasi,
  • Cissé Sow,
  • Giorgio Trinchieri,
  • Jean-Jacques Trochon,
  • Georg Zeller,
  • Nicola Segata,
  • Guido Kroemer

摘要

The European Union-sponsored ONCOBIOME network has spurred an international effort to identify and validate relevant gut microbiota-related biomarkers in oncology, generating a unique and publicly available microbiome resource. ONCOBIOME explores the effects of the microbiota on gut permeability and metabolism as well as on antimicrobial and antitumor immune responses. Methods for the diagnosis of gut dysbiosis have been developed based on oncomicrobiome signatures associated with the diagnosis, prognosis and treatment responses in patients with cancer. The mechanisms explaining how dysbiosis compromises natural or therapy-induced immunosurveillance have been explored. Through its integrative approach of leveraging multiple cohorts across populations, cancer types and stages, ONCOBIOME has laid the theoretical and practical foundations for the recognition of microbiota alterations as a hallmark of cancer. ONCOBIOME has launched microbiota-centered interventions and lobbies in favor of official guidelines for avoiding diet-induced or iatrogenic (for example, antibiotic- or proton pump inhibitor-induced) dysbiosis. Here, we review the key advances of the ONCOBIOME network and discuss the progress toward translating these into oncology clinical practice.